MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

Last update: 28 Feb, 12:32AM

123.82

4.52 (3.79%)

  • 1D 3.79%
  • 5D 3.79%
  • 1M 5.24%
  • 6M 47.25%
  • YTD 16.32%
  • 1Y 30.82%
  • 5Y 74.95%
Previous Close 119.30
Open 119.68
Volume 9,469,829
Avg. Volume (3M) 13,441,596
Market Cap 306,131,566,592
Price / Earnings (TTM) 17.01
Price / Earnings (Forward) 23.42
Price / Sales 4.64
Price / Book 5.65
52 Weeks Range
73.31 (-40%) — 125.14 (1%)
Earnings Date 30 Apr 2026
TTM Dividend Yield 0.65%
Profit Margin 27.27%
Operating Margin (TTM) 40.06%
Diluted EPS (TTM) 6.88
Quarterly Revenue Growth (YOY) -1.60%
Quarterly Earnings Growth (YOY) 6.70%
Total Debt/Equity (MRQ) 71.99%
Current Ratio (MRQ) 1.41
Operating Cash Flow (TTM) 20.88 B
Levered Free Cash Flow (TTM) 17.12 B
Return on Assets (TTM) 13.81%
Return on Equity (TTM) 39.29%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock Merck & Company, Inc. Bullish Bullish

AIStockmoo Score

0.1
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -3.0
Technical Moving Averages 1.5
Technical Oscillators 0.5
Average 0.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MRK 306 B 0.65% 17.01 5.65
JNJ 579 B 2.11% 21.81 7.25
ABBV 404 B 0.72% 97.33 50.46
PFE 154 B 6.20% 19.89 1.75
BMY 124 B 4.84% 17.53 6.74
GSK 123 B 1.62% 16.19 5.29

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.06%
% Held by Institutions 80.62%
52 Weeks Range
73.31 (-40%) — 125.14 (1%)
Price Target Range
102.00 (-17%) — 142.00 (14%)
High 142.00 (RBC Capital, 14.68%) Buy
Median 130.00 (4.99%)
Low 102.00 (Morgan Stanley, -17.62%) Hold
Average 127.83 (3.24%)
Total 8 Buy, 4 Hold
Avg. Price @ Call 112.66
Firm Date Target Price Call Price @ Call
RBC Capital 25 Feb 2026 142.00 (14.68%) Buy 122.46
Barclays 20 Feb 2026 140.00 (13.07%) Buy 122.26
Guggenheim 06 Feb 2026 140.00 (13.07%) Buy 121.93
Cantor Fitzgerald 04 Feb 2026 120.00 (-3.09%) Hold 118.33
Citigroup 04 Feb 2026 120.00 (-3.09%) Hold 118.33
27 Jan 2026 115.00 (-7.12%) Hold 107.92
Wells Fargo 04 Feb 2026 135.00 (9.03%) Buy 118.33
TD Cowen 20 Jan 2026 120.00 (-3.09%) Hold 109.45
Wolfe Research 08 Jan 2026 135.00 (9.03%) Buy 110.99
UBS 07 Jan 2026 130.00 (4.99%) Buy 108.60
BMO Capital 18 Dec 2025 130.00 (4.99%) Buy 100.69
B of A Securities 15 Dec 2025 120.00 (-3.09%) Buy 100.26
Morgan Stanley 12 Dec 2025 102.00 (-17.62%) Hold 100.30
Show more

No data within this time range.

  • 3M
Date Type Details
20 Feb 2026 CNBC With Trump's 'reciprocal' tariffs struck down, here are the industries still facing higher rates
03 Feb 2026 Announcement Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
03 Feb 2026 CNBC Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
27 Jan 2026 Announcement Merck Announces Second-Quarter 2026 Dividend
27 Jan 2026 Announcement Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
20 Jan 2026 Announcement Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Follow...
20 Jan 2026 CNBC Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
07 Jan 2026 Announcement Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
07 Jan 2026 Announcement Merck to Complete Acquisition of Cidara Therapeutics
07 Jan 2026 Announcement Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
05 Jan 2026 Announcement Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
19 Dec 2025 Announcement Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
17 Dec 2025 Announcement KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
12 Dec 2025 Announcement Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
Show more
TTM Dividend Yield 0.65%
5Y Average Dividend Yield 2.64%
Payout Ratio 45.93%
Expected Next Dividend Payment Apr 2026
Ex Date Announcement Date Payment Date Details
17 Mar 2025 28 Jan 2025 07 Apr 2025 0.81 Cash
16 Dec 2024 19 Nov 2024 08 Jan 2025 0.81 Cash
16 Sep 2024 23 Jul 2024 07 Oct 2024 0.77 Cash
17 Jun 2024 28 May 2024 08 Jul 2024 0.77 Cash
14 Mar 2024 23 Jan 2024 05 Apr 2024 0.77 Cash
14 Dec 2023 28 Nov 2023 08 Jan 2024 0.77 Cash
14 Sep 2023 25 Jul 2023 06 Oct 2023 0.73 Cash
14 Jun 2023 23 May 2023 10 Jul 2023 0.73 Cash
14 Mar 2023 24 Jan 2023 10 Apr 2023 0.73 Cash
14 Dec 2022 29 Nov 2022 09 Jan 2023 0.73 Cash
14 Sep 2022 26 Jul 2022 07 Oct 2022 0.69 Cash
14 Jun 2022 24 May 2022 08 Jul 2022 0.69 Cash
14 Mar 2022 25 Jan 2022 07 Apr 2022 0.69 Cash
14 Dec 2021 30 Nov 2021 07 Jan 2022 0.69 Cash
14 Sep 2021 27 Jul 2021 07 Oct 2021 0.65 Cash
14 Jun 2021 25 May 2021 07 Jul 2021 0.65 Cash
12 Mar 2021 26 Jan 2021 07 Apr 2021 0.65 Cash
14 Dec 2020 17 Nov 2020 08 Jan 2021 0.65 Cash
14 Sep 2020 28 Jul 2020 07 Oct 2020 0.61 Cash
12 Jun 2020 26 May 2020 07 Jul 2020 0.61 Cash
13 Mar 2020 28 Jan 2020 07 Apr 2020 0.61 Cash
13 Dec 2019 20 Nov 2019 08 Jan 2020 0.61 Cash
13 Sep 2019 24 Jul 2019 07 Oct 2019 0.55 Cash
14 Jun 2019 29 May 2019 08 Jul 2019 0.55 Cash
14 Mar 2019 30 Jan 2019 05 Apr 2019 0.55 Cash
14 Dec 2018 26 Oct 2018 08 Jan 2019 0.55 Cash
14 Sep 2018 25 Jul 2018 05 Oct 2018 0.48 Cash
14 Jun 2018 23 May 2018 09 Jul 2018 0.48 Cash
14 Mar 2018 24 Jan 2018 06 Apr 2018 0.48 Cash
14 Dec 2017 29 Nov 2017 08 Jan 2018 0.48 Cash
14 Sep 2017 26 Jul 2017 06 Oct 2017 0.47 Cash
13 Jun 2017 24 May 2017 10 Jul 2017 0.47 Cash
13 Mar 2017 28 Feb 2017 07 Apr 2017 0.47 Cash
13 Dec 2016 22 Nov 2016 09 Jan 2017 0.47 Cash
13 Sep 2016 26 Jul 2016 07 Oct 2016 0.46 Cash
13 Jun 2016 25 May 2016 08 Jul 2016 0.46 Cash
11 Mar 2016 24 Feb 2016 07 Apr 2016 0.46 Cash
11 Dec 2015 24 Nov 2015 08 Jan 2016 0.46 Cash
11 Sep 2015 22 Jul 2015 07 Oct 2015 0.45 Cash
11 Jun 2015 26 May 2015 08 Jul 2015 0.45 Cash
12 Mar 2015 24 Feb 2015 08 Apr 2015 0.45 Cash
11 Dec 2014 25 Nov 2014 08 Jan 2015 0.45 Cash
11 Sep 2014 23 Jul 2014 07 Oct 2014 0.44 Cash
12 Jun 2014 27 May 2014 08 Jul 2014 0.44 Cash
13 Mar 2014 25 Feb 2014 07 Apr 2014 0.44 Cash
12 Dec 2013 26 Nov 2013 08 Jan 2014 0.44 Cash
12 Sep 2013 23 Jul 2013 07 Oct 2013 0.43 Cash
13 Jun 2013 28 May 2013 08 Jul 2013 0.43 Cash
13 Mar 2013 26 Feb 2013 05 Apr 2013 0.43 Cash
13 Dec 2012 27 Nov 2012 08 Jan 2013 0.43 Cash
13 Sep 2012 24 Jul 2012 05 Oct 2012 0.42 Cash
13 Jun 2012 22 May 2012 09 Jul 2012 0.42 Cash
13 Mar 2012 28 Feb 2012 06 Apr 2012 0.42 Cash
13 Dec 2011 10 Nov 2011 09 Jan 2012 0.42 Cash
13 Sep 2011 26 Jul 2011 07 Oct 2011 0.38 Cash
13 Jun 2011 24 May 2011 08 Jul 2011 0.38 Cash
11 Mar 2011 22 Feb 2011 07 Apr 2011 0.38 Cash
13 Dec 2010 23 Nov 2010 07 Jan 2011 0.38 Cash
13 Sep 2010 27 Jul 2010 07 Oct 2010 0.38 Cash
11 Jun 2010 26 May 2010 08 Jul 2010 0.38 Cash
11 Mar 2010 23 Feb 2010 07 Apr 2010 0.38 Cash
11 Dec 2009 24 Nov 2009 08 Jan 2010 0.38 Cash
02 Sep 2009 28 Jul 2009 01 Oct 2009 0.38 Cash
04 Jun 2009 27 May 2009 01 Jul 2009 0.38 Cash
04 Mar 2009 24 Feb 2009 01 Apr 2009 0.38 Cash
03 Dec 2008 25 Nov 2008 02 Jan 2009 0.38 Cash
03 Sep 2008 22 Jul 2008 01 Oct 2008 0.38 Cash
04 Jun 2008 27 May 2008 01 Jul 2008 0.38 Cash
05 Mar 2008 26 Feb 2008 01 Apr 2008 0.38 Cash
05 Dec 2007 27 Nov 2007 02 Jan 2008 0.38 Cash
05 Sep 2007 24 Jul 2007 01 Oct 2007 0.38 Cash
06 Jun 2007 22 May 2007 02 Jul 2007 0.38 Cash
07 Mar 2007 27 Feb 2007 02 Apr 2007 0.38 Cash
06 Dec 2006 28 Nov 2006 02 Jan 2007 0.38 Cash
30 Aug 2006 25 Jul 2006 02 Oct 2006 0.38 Cash
31 May 2006 23 May 2006 03 Jul 2006 0.38 Cash
31 Aug 2005 26 Jul 2005 03 Oct 2005 0.38 Cash
01 Jun 2005 24 May 2005 01 Jul 2005 0.38 Cash
02 Mar 2005 22 Feb 2005 01 Apr 2005 0.38 Cash
01 Dec 2004 23 Nov 2004 03 Jan 2005 0.38 Cash
01 Sep 2004 27 Jul 2004 01 Oct 2004 0.38 Cash
02 Jun 2004 25 May 2004 01 Jul 2004 0.37 Cash
03 Mar 2004 24 Feb 2004 01 Apr 2004 0.37 Cash
03 Dec 2003 25 Nov 2003 02 Jan 2004 0.37 Cash
03 Sep 2003 22 Jul 2003 01 Oct 2003 0.37 Cash
04 Jun 2003 27 May 2003 01 Jul 2003 0.36 Cash
05 Mar 2003 25 Feb 2003 01 Apr 2003 0.36 Cash
04 Dec 2002 26 Nov 2002 02 Jan 2003 0.36 Cash
04 Sep 2002 23 Jul 2002 01 Oct 2002 0.36 Cash
05 Jun 2002 28 May 2002 01 Jul 2002 0.35 Cash
06 Mar 2002 26 Feb 2002 01 Apr 2002 0.35 Cash
05 Dec 2001 27 Nov 2001 02 Jan 2002 0.35 Cash
30 Aug 2001 24 Jul 2001 01 Oct 2001 0.35 Cash
31 May 2001 22 May 2001 02 Jul 2001 0.34 Cash
07 Mar 2001 27 Feb 2001 02 Apr 2001 0.34 Cash
06 Dec 2000 28 Nov 2000 02 Jan 2001 0.34 Cash
30 Aug 2000 25 Jul 2000 02 Oct 2000 0.34 Cash
31 May 2000 22 May 2000 03 Jul 2000 0.29 Cash
01 Mar 2000 22 Feb 2000 03 Apr 2000 0.29 Cash
01 Dec 1999 23 Nov 1999 03 Jan 2000 0.29 Cash
01 Sep 1999 27 Jul 1999 01 Oct 1999 0.29 Cash
02 Jun 1999 25 May 1999 01 Jul 1999 0.27 Cash
03 Mar 1999 23 Feb 1999 01 Apr 1999 0.27 Cash
02 Dec 1998 24 Nov 1998 04 Jan 1999 0.54 Cash
02 Sep 1998 28 Jul 1998 01 Oct 1998 0.54 Cash
03 Jun 1998 26 May 1998 01 Jul 1998 0.45 Cash
04 Mar 1998 24 Feb 1998 01 Apr 1998 0.45 Cash
03 Dec 1997 25 Nov 1997 02 Jan 1998 0.45 Cash
03 Sep 1997 22 Jul 1997 01 Oct 1997 0.45 Cash
05 Jun 1997 28 May 1997 01 Jul 1997 0.42 Cash
05 Mar 1997 25 Feb 1997 01 Apr 1997 0.42 Cash
05 Dec 1996 26 Nov 1996 02 Jan 1997 0.4 Cash
04 Sep 1996 23 Jul 1996 01 Oct 1996 0.4 Cash
06 Jun 1996 29 May 1996 01 Jul 1996 0.34 Cash
06 Mar 1996 27 Feb 1996 01 Apr 1996 0.34 Cash
06 Dec 1995 28 Nov 1995 02 Jan 1996 0.34 Cash
05 Sep 1995 25 Jul 1995 02 Oct 1995 0.34 Cash
02 Jun 1995 23 May 1995 03 Jul 1995 0.3 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.62 2 1.54
2024 3.08 4 3.10
2023 2.92 4 2.68
2022 2.76 4 2.49
2021 2.60 4 3.39
2020 2.44 4 3.13
2019 2.20 4 2.54
2018 1.92 4 2.63
2017 1.88 4 3.50
2016 1.84 4 3.28
2015 1.80 4 3.57
2014 1.76 4 3.25
2013 1.72 4 3.60
2012 1.68 4 4.30
2011 1.52 4 4.23
2010 1.52 4 4.42
2009 1.52 4 4.36
2008 1.52 4 5.24
2007 1.52 4 2.74
2006 0.760 2 1.83
2005 1.52 4 5.01
2004 1.49 4 4.86
2003 1.45 4 3.29
2002 1.41 4 2.61
2001 1.37 4 2.44
2000 1.21 4 1.35
1999 1.37 4 2.14
1998 1.89 4 2.69
1997 1.69 4 3.34
1996 1.42 4 3.74
1995 0.640 2 2.04
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria